Pixie Dust Technologies Reports First-Half Fiscal Year 2024 Financial Results

Rhea-AI Summary

Pixie Dust Technologies, Inc. (PXDT) reported strong financial results for the six months ended October 31, 2023, with total revenue increasing by 88.6% to approximately ¥299.1 million ($2.0 million). Product sales saw a significant increase, driven by the successful launches of SonoRepro, kikippa, and iwasemi products. However, service sales declined due to a shift in focus towards product commercialization. The company also experienced a net loss of ¥1.2 billion ($7.6 million) for the period.

Positive

• Total revenue increased by 88.6% to approximately ¥299.1 million ($2.0 million) for the six months ended October 31, 2023.
• Product sales rose to approximately ¥225.7 million ($1.5 million), driven by successful product launches.
• Research and development expenses decreased by 17.6% to ¥279.4 million ($1.8 million) due to a focus on product commercialization.
• The company reported a net loss of ¥1.2 billion ($7.6 million) for the six months ended October 31, 2023.
• Cash and cash equivalents stood at ¥2.4 billion ($16.0 million) as of October 31, 2023, compared to ¥2.1 billion ($15.7 million) as of April 30, 2023.

Negative

• Service sales declined to ¥73.4 million ($0.5 million) in the six months ended October 31, 2023.
• Selling, general, and administrative expenses increased by 63.3% to ¥1.1 billion ($6.9 million) for the six months ended October 31, 2023.

Financial Analyst

The reported 88.6% increase in total revenue for Pixie Dust Technologies is a significant indicator of the company's growth trajectory, especially considering the substantial rise in product sales revenue. This uptick suggests successful product launches and market acceptance, which can be a positive signal to investors about the company's potential to scale and capture market share. However, investors should also note the decline in services sales, which could indicate a strategic pivot or a potential area of weakness in the company's service offerings.

Notably, the decrease in research and development expenses by 17.6% might reflect a shift towards commercialization, but it raises questions about the company's long-term innovation pipeline. While reduced R&D spending can improve short-term profitability, it is essential to ensure that the company does not underinvest in future growth drivers. On the other hand, the 63.3% increase in selling, general and administrative expenses is typical for a company in an expansion phase, investing heavily in marketing and infrastructure to support its growing operations.

The reported net loss widening from the previous year is a concern and warrants close monitoring. Investors should evaluate whether this is a temporary effect of the company's growth investments or indicative of deeper issues. The increase in other income, primarily from foreign exchange gains, is a non-operational factor that investors should consider as it may not be sustainable in the long term.

The company's cash position appears healthy, with an increase in cash and cash equivalents. This provides the company with a cushion for operational needs and potential investments. However, the effectiveness of capital allocation strategies should be scrutinized to ensure that cash reserves are used to generate long-term shareholder value.

Market Research Analyst

The introduction of a one-time purchase model for the kikippa speaker, alongside the existing subscription model, reflects the company's flexibility in adapting to different consumer preferences and revenue streams. This dual approach can attract a broader customer base and enhance market penetration.

The collaborative research agreement with Tohoku University School of Medicine and the company-sponsored experiment on the SonoRepro product represent strategic investments in innovation and credibility. Such collaborations can enhance the company's reputation in the scientific community and may lead to breakthroughs that could open new market opportunities, particularly in the non-pharmaceutical skin disease treatments segment.

Recognition at CES 2024 with an Innovation Award can have a substantial promotional effect, boosting brand visibility and potentially leading to increased sales. Awards and accolades can serve as third-party validation of a company's products, which can be influential in consumer purchasing decisions. The impact of this recognition on sales and market share will be critical to monitor in subsequent financial periods.

Economist

Foreign exchange gains played a notable role in the company's financials, which can be attributed to the volatility in the USD/JPY exchange rate. Such gains are often considered non-core to a company's primary business operations and can vary widely from period to period. Investors should be cautious in interpreting these gains as they may not be indicative of operational performance.

The company's reporting in both Japanese yen and U.S. dollars provides transparency for international investors, but it also introduces currency risk. The translation of financial statements at a specific exchange rate (¥151.46 = US$1.00) offers a snapshot of financial performance but may not fully capture the ongoing currency fluctuations that could affect the company's financials in future reporting periods.

The overall economic context, including consumer spending, technological adoption rates and competitive landscape, will be integral in assessing the sustainability of the company's revenue growth. Additionally, macroeconomic factors such as inflation, interest rates and international trade policies could impact the company's operational costs and global expansion strategies.

NEW YORK and TOKYO, Feb. 12, 2024 /PRNewswire/ - Pixie Dust Technologies, Inc. (NasdaqCM: PXDT) (the "Company"), a Japanese technology company focused on commercializing innovative products and materials utilizing proprietary wave technology, reported financial results for the six months ended October 31, 2023.

Recent Operational Highlights

• Introduced a one-time purchase model for its proprietary speaker kikippa, in addition to the current recurring subscription model
• Announced Company-sponsored experiment on the SonoRepro™ product, conducted by Dr. Akinobu Miyata, Director of Miyata Medical Clinic, in collaboration with the Japan Clinical Trial Association
• Exhibited at CES 2024 held in Las Vegas, NV and received the Innovation Award for its iwasemi™ RC-α product
• Announced collaborative research agreement with Tohoku University School of Medicine for the purpose of developing and commercializing certain non-pharmaceutical skin disease treatments using wave control technology
• Awarded the 2023 Good Design Award for the kikippa speaker

Six Months Ended October 31, 2023 Financial Results

The Company's financial statements for the six months ended October 31, 2023 and the related notes, and related management's discussion and analysis of the Company's financial condition and results of operations can be found in the Company's Form 6-K filed with the SEC, a copy of which can also be found on the Company's website. The Company's functional currency and reporting currency is the Japanese yen (which we refer to as "JPY" or "¥"). The terms "dollar," "USD," "US$" or "$" refer to U.S. dollars, the legal currency of the United States. Convenience translations included herein of Japanese yen into U.S. dollars have been made at the exchange rate of ¥151.46 = US$1.00, which was the foreign exchange rate on October 31, 2023 as reported by the Board of Governors of the Federal Reserve System. All figures are expressed in Japanese yen and U.S. dollars unless otherwise stated.

• Total Revenue increased by 88.6% from approximately ¥158.6 million ($1.0 million) for the six months ended October 31, 2022 to ¥299.1 million ($2.0 million) for the six months ended October 31, 2023. The increase was primarily due to increases in product sales revenue, partially offset by decreases in revenue from commissioned research and development and revenue from membership service.
• Product Sales were approximately ¥225.7 million ($1.5 million) in the six months ended October 31, 2023, representing a ¥188.9 million ($1.2 million) increase from the same period in the prior year. The increase was attributable to the launches and sales of the following products: SonoRepro (launched in November 2022), kikippa (launched in April 2023), and iwasemi (launched in July 2022).
• Services Sales declined to ¥73.4 million ($0.5 million) in the six months ended October 31, 2023 from ¥121.9 million ($0.8 million) in the same period in the prior year. The decline was primarily due to the decrease in commissioned research and a shift in focus from the research and development of kikippa and other products to product commercialization.
• Research and Development Expenses decreased by 17.6% from ¥339.3 million ($2.2 million) in the six months ended October 31, 2022 to ¥279.4 million ($1.8 million) for the six months ended October 31, 2023. The decrease was primarily due to a shift in focus from the research and development of kikippa and VUEVO to product commercialization.
• Selling, General and Administrative Expenses increased by 63.3% from ¥643.9 million ($4.3 million) for the six months ended October 31, 2022 to ¥1.1 billion ($6.9 million) for the six months ended October 31, 2023. The increase was primarily due to increases in advertising and marketing expenses for new products, rent expense in connection with the Company's new headquarters and depreciation expenses.
• Other Income increased significantly from ¥0.1 million for the six months ended October 31, 2022 to ¥41.4 million ($0.3 million) for the six months ended October 31, 2023. The increase was primarily due to the increase of foreign exchange gains as a result of the receipt of the net proceeds from the initial public offering of the Company's common shares in U.S. dollars during the six months ended October 31, 2023.
• Net Loss was ¥1.2 billion ($7.6 million) in the six months ended October 31, 2023 compared to ¥885 million ($5.8 million) in the same period in the prior year.
• As of October 31, 2023, the Company had ¥2.4 billion ($16.0 million) in cash and cash equivalents, compared to ¥2.1 billion ($15.7 million) as of April 30, 2023, which were held and used for working capital purposes. The Company's cash and cash equivalents generally consist of cash on hand, demand deposits, and time deposits maintained at various financial institutions.

Forward-Looking Statements

Certain statements contained in this press release are "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect the Company's current expectations or beliefs concerning future events and actual events may differ materially from current expectations. Any such forward-looking statements are subject to various risks and uncertainties, including the strength of the economy, changes to the market for securities, political or financial instability and other factors which are set forth in the Company's prospectus that forms a part of the Registration Statement on Form F-1 (File No. 333-272476), as amended, and in all filings with the SEC made by the Company subsequent to the filing thereof. The Company does not undertake to publicly update or revise its forward-looking statements, whether as a result of new information, future events or otherwise.

About Pixie Dust Technologies, Inc.

Pixie Dust Technologies, Inc. is a Japanese technology company focused on commercializing innovative products and materials utilizing proprietary wave technology. The Company is currently focusing on two areas of product development: (1) "Personal Care & Diversity", where wave control technology is applied to mechanobiology and intervention/assistance in vision, hearing, and touch, and (2) "Workspace & Digital Transformation," where metamaterials (technology that creates properties through structure rather than material) and solutions to commercial design problems, such as in offices or construction sites, are applied.

View original content to download multimedia:https://www.prnewswire.com/news-releases/pixie-dust-technologies-reports-first-half-fiscal-year-2024-financial-results-302058339.html

SOURCE Pixie Dust Technologies

FAQ

What was the total revenue for Pixie Dust Technologies, Inc. (PXDT) for the six months ended October 31, 2023?

Total revenue increased by 88.6% to approximately ¥299.1 million ($2.0 million) for the six months ended October 31, 2023.

What products contributed to the increase in product sales for Pixie Dust Technologies, Inc. (PXDT)?

The increase in product sales was driven by the successful launches of SonoRepro, kikippa, and iwasemi products.

What was the net loss reported by Pixie Dust Technologies, Inc. (PXDT) for the six months ended October 31, 2023?

The company reported a net loss of ¥1.2 billion ($7.6 million) for the six months ended October 31, 2023.

How did the research and development expenses change for Pixie Dust Technologies, Inc. (PXDT) from the prior period?

Research and development expenses decreased by 17.6% to ¥279.4 million ($1.8 million) for the six months ended October 31, 2023.

What was the cash and cash equivalents amount for Pixie Dust Technologies, Inc. (PXDT) as of October 31, 2023?

Cash and cash equivalents stood at ¥2.4 billion ($16.0 million) as of October 31, 2023.